Clinical Trial Update: Standard Second-line Therapy With ONgericimab and TOripalimab in pMMR/MSS Colorectal Cancer: a Single-arm Phase II Trial [Phase 2]

View source ↗

Summary

A Phase II single-arm trial evaluating ONgericimab plus TOripalimab as standard second-line therapy in pMMR/MSS colorectal cancer; status is NOT_YET_RECRUITING.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• ONgericimab
• Toripalimab (Toripalimab)

Snippet

Sponsor: Shanghai Pudong Hospital | Conditions: Advanced Colorectal Cancer | Phase 2 | Status: NOT_YET_RECRUITING